Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer therapy.
Introduction

A C C E P T E D
A specially designed questionnaire was administered 4 times: (1) at baseline (after surgery and before starting treatment with chemotherapy); (2) after the 1st cycle of neurotoxic chemotherapy; (3) halfway through the planned adjuvant treatment (after the 4 th cycle of oxaliplatin for colorectal cancer, and after the 2 nd cycle of docetaxel for breast cancer), and finally; (4) at follow-up 1 year after baseline. Patients were asked to complete the questionnaire within 5 days after administration of chemotherapy and were told to answer the questionnaire also in case of early termination of chemotherapy or dose reduction during treatment. Patients were excluded if they did not complete at least 1 cycle of chemotherapy.
Information about other adjuvant treatments, the number of cycles, and the dosage of chemotherapy was collected from medical charts, and the cumulative dosage was calculated using the Mosteller formula. 23 
Questionnaire
At baseline, patients were asked about comorbidity, alcohol consumption, smoking habits, and use of medication.
A C C E P T E D
The questionnaire contained validated questionnaires described below. Quality of life was assessed using the quality of life questionnaire EQ-5D (EuroQol Group 1995), which consists of 2 parts. The 1st part contains a description of health state using 5 items: mobility, self-care, usual activities, pain/complaints, and anxiety/depression. Patients were asked to indicate for each item whether they experienced "none", "some", or "serious" health problems. The second part is a visual analog scale (VAS), ranging from 0 (worst imaginable health) to 100 (best health).
Anxiety and depression were rated using the Hospital Anxiety and Depression Scale (HADS). 31 On each subscale, a score of 0-7 indicates no anxiety or depression, and caseness of anxiety and depression is defined as a score of 8 and above.
To evaluate neuropathy symptoms, a specific questionnaire divided into 3 parts addressing the upper extremity, the lower extremity, and the orofacial area was used. 17 Patients were asked if they had specific symptoms (yes/no). The questionnaire contains questions about dysesthesia, eg, burning pain with or without cold, a greater than normal sense of touch, and paresthesia, eg, tingling, numbness, and difficulty feeling things.
Patients were also asked to complete the Pain Catastrophizing Scale (PCS). 28 The questionnaire includes 3 dimensions: rumination, magnification, and helplessness. In addition, a total score indicates the level of pain catastrophizing.
In order to distinguish neuropathic from non-neuropathic pain, 3 identical versions of
PainDETECT was used, 11 1 for reporting pain in the hands and/or feet, 1 for reporting pain in the orofacial area, and 1 for reporting other pain. PainDETECT comprises 7 questions on specific neuropathic pain symptoms, which the patients were asked to rate on a 0 (never) to 5 (very strongly)
scale. In detail, the questions address the following 7 sensory symptoms: spontaneous burning pain, spontaneous paresthesia, dynamic mechanical allodynia (allodynia), spontaneous pain attacks,
thermal hyperalgesia, numbness, and pressure-evoked pain. Distinction was made by establishing scores based on the assessment of sensory symptomatology.
For analysis of predictors, we defined chronic CIPN symptoms as tingling and/or numbness in the feet in patients without pre-existing neuropathic symptoms (tingling or numbness).
15,20,21
Statistical Analysis
Stata/IC 12.1 (StataCorp LP, College Station, TX, USA) was used for all statistical analyses.
Normality was checked using histograms and QQ-plots. Numerical data were analyzed depending on the distribution using unpaired t-test (normal distribution) or Wilcoxon rank-sum (MannWhitney) test (non-normal distribution). The results are expressed as mean values ± SD.
Categorical data were analyzed using the Χ 2 test except when the data was sparse, in which case
Fisher's exact test was applied. The risk of developing chronic CIPN symptoms was described using a logistic regression model. Estimates are given with exact 95% confidence intervals. Pvalues < 0.05 were considered statistically significant.
Results
A total of 176 consecutive patients were recruited for the study; 2 patients were excluded because they never received the planned chemotherapy. Thus, 100 patients in the docetaxel group and 74 patients in the oxaliplatin group were included. The response rate was 72% after 1 cycle, 55%
halfway through adjuvant treatment, and 93% at 1-year follow-up. Patients in the oxaliplatin group were significantly different from patients in the docetaxel group in terms of age and height, which was expected since this group consisted of both male (59%) and female (41%) patients ( Table 1) .
Dose reduction and early discontinuation, in particular because of neuropathy, were more frequent in the oxaliplatin group than in the docetaxel group ( Table 1 ). In the docetaxel group, a number of
patients received other adjuvant treatments following docetaxel; 85% of patients received adjuvant treatment with radiation therapy, 72% with endocrine therapy, depending on hormonal status either tamoxifen or an aromatase inhibitor, which are both antiestrogen treatments, and 27% with trastuzumab. In the oxaliplatin group, 73% of patients received CaMg infusion, starting when they experienced persistent neuropathy symptoms during treatments.
Development of neuropathy symptoms
The most common neuropathy symptoms 17 were tingling, numbness, a greater than normal sense of touch, and burning pain or discomfort with cold. Tingling was the most common symptom both in the hands and feet in both groups ( Fig. 1 and Table 2 ), and was still present in 34-45% in both groups at 1-year follow-up. Pain and discomfort with cold during treatment were most prominent in the oxaliplatin group, with almost no patients in the docetaxel group experiencing cold-induced symptoms. Numbness increased from baseline to follow-up both in the hands and feet in both groups and was together with tingling the most prominent symptom at 1-year follow-up. A greater than normal sense of touch developed less frequently.
Chronic CIPN Symptoms
Tingling and/or numbness in the feet were present in 10 patients in the oxaliplatin group and in 7 patients in the docetaxel group at baseline; 9 of these patients had diabetes, which could explain the symptoms. In the oxaliplatin group, 35 patients (63.6%) met the predefined criteria for having CIPN symptoms at the 1-year follow-up, compared with 39 (44.8%) in the docetaxel group. In the oxaliplatin group, the cumulative dose was significantly higher in those who reported neuropathy symptoms at 1-year follow-up (Table 3 and Fig. 2 ). Adjusting for cumulative dose using logistic regression analyses did not reveal any other associations of baseline and treatment characteristics
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and the development of neuropathy symptoms. In the docetaxel group, there was no significant difference between patients with and without symptoms of neuropathy in terms of baseline-and treatment-related characteristics (Table 3) .
Chronic Pain
At 1-year follow-up, orofacial pain was reported by 4 (6.0%) patients and other pain by 7 (10.4%) patients in the oxaliplatin group, whereas 4 (4.3%) patients in the docetaxel group reported orofacial pain and 34 (36.2%) other pain. The most common pain symptoms reported as other pain were pressure-evoked pain, attacks, burning pain, and numbness, but less than 25% of patients reported these symptoms as being at least moderate. (25%) patients did not meet the criteria for CIPN symptoms and 9 patients had ≤ 2 symptoms according to the PainDETECT, suggesting that the presence of pain was not related to CIPN in some of these patients.
A C C E P T E D
When comparing patients in the 2 groups with and without pain in the hands or feet, after excluding patients with neuropathy symptoms at baseline, no significant difference in terms of BMI, smoking status, alcohol consumption, and cumulative dose of chemotherapy was seen (Table   3) ; however, in the oxaliplatin group, significantly more patients with possible CIPN-related pain were reduced in dose due to neuropathy compared with patients without pain (P = 0.02). Analyses of risk factor variables using logistic regression and adjusting for dose reduction did not result in any baseline risk factor variables associated with pain in the hands and/or feet. In the docetaxel group, a significantly higher number of patients with pain in the hands and feet were treated with adjuvant endocrine therapy compared with patients without pain (P = 0.04; Table 3 ). No other risk factor variables were associated with increased risk, nor when adjusting for endocrine therapy using logistic regression.
Anxiety, Depression, and Quality of Life
Development of anxiety and depression during and after chemotherapy followed the same pattern in both patient groups with decreasing anxiety and increasing depression over time ( Fig. 4A and Table 2 ). Comparing HADS scores in patients with and without pain at 1-year follow-up, there was a significant difference in the change score for both anxiety and depression in the docetaxel group (Fig. 4B) . The same pattern was seen in the oxaliplatin group, but the change was not significant (data not shown). Pain catastrophizing scores were low in both groups ( Table 2) .
The results of the EQ-5D are shown in Fig. 5 . Patients in the docetaxel group generally reported more problems in quality of life during chemotherapy compared with patients in the oxaliplatin group, but the 2 groups were comparable at 1-year follow-up. Patient-rated health state was high in both groups, above 80% at follow-up (Fig. 5) .
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DISCUSSION
The results of this prospective study comparing adjuvant oxaliplatin and docetaxel treatment showed that neuropathy symptoms were a frequent complication that persisted after treatment in 43% of patients. Furthermore, although CIPN is often seen as 1 entity, there are important differences between the 2 types of treatment. While the study supported previous findings of a gradual development of a length-dependent sensory large-fiber polyneuropathy with tingling and numbness in the feet (L. Ventzel et al. unpublished), 8 the development of neuropathy symptoms during chemotherapy was very different in the 2 groups, with a high frequency of patients with cold allodynia in the oxaliplatin group, whereas this symptom was almost non-existing in the docetaxel group. Neuropathy symptoms were in general more common during oxaliplatin treatment compared with docetaxel treatment. Our results also showed that chronic pain in the hands and feet following oxaliplatin treatment was often related to CIPN, while in patients treated with docetaxel, this type of pain was unrelated to neuropathy in several cases and more likely explained by other adjuvant treatments. These differences as well as the heterogeneity in the mechanisms of the nerve injury caused by the 2 neurotoxic agents 5 give rise to the question if it is reasonable to pool patients who are treated with different neurotoxic agents when trying to identify risk factors or testing drugs to treat or prevent CIPN. It seems more reasonable and probably more effective to use a mechanismbased strategy or to pool patients with similar patterns of clinical symptoms, which has been suggested in other studies. 7 Our study confirms that oxaliplatin results in both an acute neuropathy with tingling sensations and cold-evoked symptoms affecting mainly the hands and a chronic length-dependent primarily sensory neuropathy resulting in loss of sensation, dysesthesia, and pain typically affecting the feet.
While severity of acute symptoms has been suggested to predict chronic neuropathy, 3,24 it is also likely that mechanisms differ, since acute symptoms, in contrast to the chronic neuropathy, occur in A C C E P T E D the absence of abnormalities in sensory nerve conduction velocities and may be related to changes in Na + conductances 24 .
In accordance with other studies, the results of our study showed that CIPN and pain affected the patients' quality of life, 26,29 although they rated their general health state as high. This could, however, be a simple expression of the fact that they believe that they no longer have cancer. Other explanations might be that they are working to treat the cancer or that they have a new realization of the importance of life. Comparing patients with and without pain in the hands and feet in the docetaxel group, patients with persistent pain had significantly less improvement in anxiety and depression scores than those without persistent pain, suggesting that pain has a significant effect on psychological functioning, although it is also possible that persistent anxiety and depressive symptoms increase the reporting of pain 13 .
Patients with pain in the oxaliplatin group were more often reduced in dose and received calcium/magnesium during treatment, which at the time of the study was supposed to reduce the risk of neuropathic symptoms. Severe symptoms due to neurotoxicity despite a reduction in dose were also seen in another large study, 4 and we support their recommendations to decrease the cumulative dose in patients presenting with neuropathy on time. A recent randomized, controlled trial showed that calcium/magnesium has no effect in oxaliplatin-induced sensory neuropathy. 19 At the time of the study calcium/magnesium infusions were given together with oxaliplatin when patients complained of neuropathy. This may have resulted in an additional cycle of oxaliplatin, rather than reducing the dose and it is therefore speculated that the use of calcium/magnesium allowed patients to receive a higher cumulative dose of oxaliplatin and thus increased their risk of chronic symptoms. Another possibility is that patients with chronic pain had more symptoms of neurotoxicity during treatment.
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Comparing neuropathic pain symptoms at follow-up, patients in the docetaxel group reported significantly less burning, temperature-evoked pain, pricking, and numbness than pain patients in the oxaliplatin group. Pressure-evoked pain, however, was more frequent in the docetaxel group.
Patients with pain in the docetaxel group were significantly more often treated with adjuvant endocrine therapy compared with patients without pain, and 25% of patients with pain did not meet the pre-defined criteria for neuropathy. Due to low estrogen levels and possible other unknown underlying mechanisms adjuvant endocrine therapy is known to cause arthralgia, myalgia, joint stiffness, paresthesia, and carpal tunnel syndrome, 18 which may be misinterpreted as chemotherapyinduced neuropathic pain by both clinicians and patients. Recent studies have suggested that muscle and joint pain should be considered a part of the neuropathic syndrome, 10,12 but it is possible that these neuropathic-like symptoms are caused by endocrine therapy and are not a part of the CIPN syndrome. This is supported by results of a study on persistent sensory disturbances after adjuvant chemotherapy for breast cancer that showed that endocrine treatment was a risk factor for peripheral sensory disturbances in the feet of patients receiving cyclophosphamide, epirubicin, and fluorouracil, which is not known to cause neuropathy and neuropathic pain. 2 In order to give patients the best possible treatment, it is important to distinguish neuropathic pain from nociceptive pain. 14 An important limitation to this study is the use of questionnaires without clinical examinations; however studies have showed that numbness in the lower extremities has the highest efficiency for correctly classifying painful sensory neuropathy. 20 In conclusion, the results of our study showed that CIPN symptoms are a frequent complication, which may persist after finishing chemotherapy. However, there are important differences between the different drugs, and chronic pain in the hands and feet following oxaliplatin treatment was often related to CIPN, while in patients treated with docetaxel, this type of pain was in some cases unrelated to neuropathy and more likely explained by other adjuvant treatments. This
diversity could explain the result of a recent large randomized, placebo-controlled, crossover trial showing that duloxetine was more efficacious for oxaliplatin-induced than paclitaxel-induced painful neuropathy. 27 Collectively, these results call for further studies which should focus on characterizing and separating CIPN-related pain from CIPN without pain and other types of pain, since this will help determine the best outcome measure for future trials on prevention and/or treatment of CIPN and CIPN-related pain.
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